Opioid Related Disorder Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Anebulo Pharmaceuticals, Indivior, Opiant Pharmaceuticals, NFL Biosciences

Opioid Related Disorder Disorder pipeline constitutes 10+ key companies continuously working towards developing 10+ Opioid Related Disorder Disorder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Opioid Related Disorder Disorder Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Opioid Related Disorder Disorder Market.

The Opioid Related Disorder Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Opioid Related Disorder Disorder Pipeline Report: https://www.delveinsight.com/sample-request/opioid-related-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Opioid Related Disorder Disorder treatment therapies with a considerable amount of success over the years. Opioid Related Disorder Disorder Key players such as - Opiant Pharmaceuticals, NFL Biosciences, Anebulo Pharmaceuticals, Indivior, and others, are developing therapies for the Opioid Related Disorder Disorder treatment
• Opioid Related Disorder Disorder Emerging therapies such as - OPNT004, NFL-201, ANEB-001, AEF0117, and others are expected to have a significant impact on the Opioid Related Disorder Disorder market in the coming years.
• In February 2025, Glucagon-like peptide receptor agonists (GLP-1RAs), such as Novo Nordisk's semaglutide (Ozempic, Wegovy) and Eli Lilly's tirzepatide (Mounjaro, Zepbound), have gained widespread attention for their blockbuster sales in treating diabetes and obesity. As interest in these therapies grows, research is expanding beyond metabolic disorders to explore their potential in cardiovascular, neurodegenerative, and respiratory diseases. Now, these drugs are also being investigated for a surprising new application: opioid use disorder (OUD).
• In October 2024, ANANDA Scientific Inc., a biopharmaceutical company focused on research, has announced the start of a clinical trial to evaluate NantheiaTM ATL5, an investigational drug that combines cannabidiool with delta-9-tetrahydrocannabinol (THC). The drug utilizes ANANDA's proprietary delivery technology and is being tested for its potential effectiveness in treating co-occurring opioid use disorder (OUD) and chronic pain. (Clinical Trials.gov Identifier: NCT06544291)
• In June 2024, Indivior has initiated a Phase II clinical trial of INDV-2000 by administering the first dose to a participant with opioid use disorder (OUD). This randomized, double-blind, placebo-controlled study will assess the safety and efficacy of the treatment over three months in individuals with moderate to severe OUD who are seeking treatment.

Opioid Related Disorder Disorder Overview
Opioid-Related Disorder refers to a group of conditions caused by the misuse of opioid drugs, including prescription painkillers (like oxycodone, hydrocodone, and morphine) and illicit opioids (such as heroen or fentanyl). It includes opioid use disorder (OUD), dependence, withdrawal, intoxication, and overdose. The disorder leads to physical dependence, psychological addiction, and severe health consequences, including respiratory depression and increased risk of overdose. Treatment options include medications (like methadone, buprenorphine, and naloxone), behavioral therapies, and rehabilitation programs to help manage addiction and withdrawal symptoms.

Get a Free Sample PDF Report to know more about Opioid Related Disorder Disorder Pipeline Assessment-
https://www.delveinsight.com/report-store/opioid-related-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Opioid Related Disorder Disorder Pipeline Therapeutics Assessment
• Opioid Related Disorder Disorder Assessment by Product Type
• Opioid Related Disorder Disorder By Stage and Product Type
• Opioid Related Disorder Disorder Assessment by Route of Administration
• Opioid Related Disorder Disorder By Stage and Route of Administration
• Opioid Related Disorder Disorder Assessment by Molecule Type
• Opioid Related Disorder Disorder by Stage and Molecule Type

DelveInsight's Opioid Related Disorder Disorder Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Download Sample PDF Report to know more about Opioid Related Disorder Disorder drugs and therapies:
https://www.delveinsight.com/sample-request/opioid-related-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Opioid Related Disorder Disorder Drugs Under Different Phases of Clinical Development Include:
• OPNT004: Opiant Pharmaceuticals
• NFL-201: NFL Biosciences
• ANEB-001: Anebulo Pharmaceuticals
• AEF0117: Indivior

Opioid Related Disorder Disorder Pipeline Analysis:
The Opioid Related Disorder Disorder pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Opioid Related Disorder Disorder treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Opioid Related Disorder Disorder Treatment.
• Opioid Related Disorder Disorder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Opioid Related Disorder Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Opioid Related Disorder Disorder market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Opioid Related Disorder Disorder product details are provided in the report. Download the Opioid Related Disorder Disorder pipeline report to learn more about the emerging Opioid Related Disorder Disorder therapies at:
https://www.delveinsight.com/sample-request/opioid-related-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Opioid Related Disorder Disorder Pipeline Market Drivers
• With more states and countries opening up to legal Substance Drug Abuse, there are growing concerns about a rise in addiction

Opioid Related Disorder Disorder Pipeline Market Barriers
• Much remains to be learned in order to advance public health and to guide personal and societal decisions regarding the use of Substance Drug Abuse
• Substance Drug Abuse is the most common substance of abuse besides alcohol and tobacco, and there is no FDA approved drug

Scope of Opioid Related Disorder Disorder Pipeline Drug Insight
• Coverage: Global
• Key Opioid Related Disorder Disorder Companies: Opiant Pharmaceuticals, NFL Biosciences, Anebulo Pharmaceuticals, Indivior, and others
• Key Opioid Related Disorder Disorder Therapies: OPNT004, NFL-201, ANEB-001, AEF0117, and others
• Opioid Related Disorder Disorder Therapeutic Assessment: Opioid Related Disorder Disorder current marketed and Opioid Related Disorder Disorder emerging therapies
• Opioid Related Disorder Disorder Market Dynamics: Opioid Related Disorder Disorder market drivers and Opioid Related Disorder Disorder market barriers

Request for Sample PDF Report for Opioid Related Disorder Disorder Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/opioid-related-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Opioid Related Disorder Disorder Report Introduction
2 Opioid Related Disorder Disorder Executive Summary
3 Opioid Related Disorder Disorder Overview
4 Opioid Related Disorder Disorder- Analytical Perspective In-depth Commercial Assessment
5 Opioid Related Disorder Disorder Pipeline Therapeutics
6 Opioid Related Disorder Disorder Late Stage Products (Phase II/III)
7 Opioid Related Disorder Disorder Mid Stage Products (Phase II)
8 Opioid Related Disorder Disorder Early Stage Products (Phase I)
9 Opioid Related Disorder Disorder Preclinical Stage Products
10 Opioid Related Disorder Disorder Therapeutics Assessment
11 Opioid Related Disorder Disorder Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Opioid Related Disorder Disorder Key Companies
14 Opioid Related Disorder Disorder Key Products
15 Opioid Related Disorder Disorder Unmet Needs
16 Opioid Related Disorder Disorder Market Drivers and Barriers
17 Opioid Related Disorder Disorder Future Perspectives and Conclusion
18 Opioid Related Disorder Disorder Analyst Views
19 Appendix
20 About DelveInsight

Latest Reports by DelveInsight
• India Healthcare Report: https://www.delveinsight.com/report-store/india-healthcare-outlook-report
• Implantable Cardioverter Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Monkeypox Market: https://www.delveinsight.com/report-store/monkeypox-market
• Antibody Drug Conjugate Market: https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Tbi Market: https://www.delveinsight.com/report-store/traumatic-brain-injury-market
• Indwelling Catheters Market: https://www.delveinsight.com/report-store/indwelling-catheters-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.